Hikma Pharmaceuticals Dividends - HIK

Hikma Pharmaceuticals Dividends - HIK

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Hikma Pharmaceuticals Plc HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change Price Change % Stock Price Last Trade
-2.00 -0.08% 2,632.00 16:29:59
Open Price Low Price High Price Close Price Previous Close
2,644.00 2,560.00 2,644.00 2,632.00 2,634.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Hikma Pharmaceuticals HIK Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
07/08/2020InterimUSX1631/12/201931/12/202020/08/202021/08/202021/09/20200
27/02/2020FinalUSX3031/12/201831/12/201919/03/202020/03/202007/05/202044
09/08/2019InterimUSX1431/12/201831/12/201922/08/201923/08/201923/09/20190
13/03/2019FinalUSX2631/12/201731/12/201804/04/201905/04/201922/05/201938
15/08/2018InterimUSX1231/12/201731/12/201823/08/201824/08/201821/09/20180
14/03/2018FinalUSX2331/12/201631/12/201705/04/201806/04/201824/05/201834
17/08/2017InterimUSX1131/12/201631/12/201724/08/201725/08/201722/09/20170
15/03/2017FinalUSX2231/12/201531/12/201606/04/201707/04/201725/05/201733
26/08/2016InterimUSX1131/12/201531/12/201601/09/201602/09/201630/09/20160
16/03/2016FinalUSX2131/12/201431/12/201507/04/201608/04/201619/05/201632
19/08/2015InterimUSX1131/12/201431/12/201527/08/201528/08/201525/09/20150
11/03/2015FinalUSX9.931/12/201331/12/201416/04/201517/04/201521/05/201516.9
11/03/2015SpecialUSX431/12/201331/12/201416/04/201517/04/201521/05/20150
20/08/2014InterimUSX731/12/201331/12/201427/08/201429/08/201426/10/20140
20/08/2014SpecialUSX431/12/201331/12/201427/08/201429/08/201426/10/20140
12/03/2014SpecialUSX2.431/12/201231/12/201323/04/201425/04/201422/05/20140
12/03/2014FinalUSX7.831/12/201231/12/201323/04/201425/04/201422/05/201412.3
21/08/2013InterimUSX4.531/12/201231/12/201304/09/201306/09/201307/10/20130
21/08/2013SpecialUSX1.931/12/201231/12/201304/09/201306/09/201307/10/20130
13/03/2013FinalUSX1031/12/201131/12/201217/04/201319/04/201323/05/201316
16/08/2012InterimUSX631/12/201131/12/201229/08/201231/08/201208/10/20120
14/03/2012FinalUSX7.531/12/201031/12/201118/04/201220/04/201224/05/201213
25/08/2011InterimUSX5.531/12/201031/12/201107/09/201109/09/201113/10/20110
16/03/2011FinalUSX7.531/12/200931/12/201013/04/201115/04/201126/05/201113
26/08/2010InterimUSX5.531/12/200931/12/201008/09/201010/09/201014/10/20100
17/03/2010FinalUSX6.531/12/200831/12/200914/04/201016/04/201027/05/201011
17/03/2009FinalUSX431/12/200731/12/200829/04/200901/05/200902/06/20097.5
27/08/2009InterimUSX4.530/12/200730/06/200816/09/200918/09/200916/10/20090
28/08/2008InterimUSX3.530/12/200730/06/200817/09/200819/09/200817/10/20080
18/03/2008FinalUSX401/07/200731/12/200730/04/200802/05/200802/06/20087.5
05/09/2007InterimUSX3.530/12/200630/06/200726/09/200728/09/200726/10/20070
20/03/2007FinalUSX2.131/12/200531/12/200616/05/200718/05/200718/06/20073.7
13/09/2006InterimUSX1.630/12/200530/06/200627/09/200629/09/200627/10/20060
25/05/2006FinalUSX0.4731/12/200431/12/200526/04/200628/04/200630/05/20060.47

Top Dividend Posts

DateSubject
07/8/2020
06:15
suetballs: Half year results look good and an increased dividend which is rare in today's markets. Optimism for the rest of the year too. Suet
08/5/2020
14:55
drsous: Has anybody received their dividend .Listed payment date 7/5/20 on advfn.
07/5/2020
19:35
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a Twin Petes Investing Podcast a few days ago and part of our discussion covers HIK. We also talked in depth about the current situation in the Markets and how we reckon things could play out. Anyway, if you use Apple or Audioboom you can find it under the 'Conkers Corner' Channel (you want TPI Podcast 22) and you can find it on Soundcloud at the link below. Ideal listening Lockdown listening !! Cheers, WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheeliedealer-22-the-winning-covid19-stocks-boo-cmcx-igg-odx-avct-plus-tsla
20/3/2020
07:39
ali47fish: the link shows many companies but not hik
09/8/2019
06:52
broadwood: Hikma Pharmaceuticals upgrades outlook amid 'strong' sales in H1 Just what the doctor ordered. StockMarketWire.com - Hikma Pharmaceuticals raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products. The company said it expected full-year Injectables revenue to be in the range of $870m to $900m and core operating margin to be in the range of 36% to 38%. Generics revenue for the full year was expected to be in the range of $690m to $720m, with core operating margin in the range of 16% to 18%. Branded revenue, meanwhile, was expected to be higher in the second half of the year and with revenue growth in constant currency to be in the mid-single digits. The upgraded outlook comes as the company saw profits jumped on the back of an increase in revenues. For the six months ended 30 June 2019, pre-tax profits rose to $226m from $141m a year earlier and revenue grew 8% to $1,047m, reflecting 'strong sales of our in-market products and new product launches,' the company said. The interim dividend was raised by 17% to 14 cents per share.
14/3/2019
20:20
karateboy: Dividend increased by almost 21%. The only reason I see for share price drop is pound strenghing impacting dividend conversion from $ to £. It will recover.
15/8/2018
07:30
broadwood: Generic drugmaker Hikma Pharmaceuticals issued its interim results for the six months ended 30 June on Wednesday, reporting an 11% improvement in group revenue to $989m, or 10% in constant currency. The FTSE 250 company said its operating profit for the period was $174m, up 54%, while core group operating profit rose 22% to $214m, or 23% in constant currency. Core basic earnings per share totalled 61.4 US cents, up 35%, and 38% in constant currency, with basic earnings per share rising 53% to 44.0 cents, or 57% in constant currency. Cash flow from operations reached $185m. Hikma said its net debt fell to $501m, from $546m at the end of December, with “healthy”; leverage ratios maintained. Its board declared an interim dividend of 12 cents per share, up from 11 cents per share a year ago. The company also raised its guidance for the injectables and generics businesses, and reiterated it for the branded business. “I am pleased with our first half performance, with each of our three business segments achieving revenue and, importantly, profit growth,” said Hikma chief executive officer Siggi Olafsson. “Our injectables business continues to demonstrate resilience. “Our broad portfolio, extensive manufacturing capabilities and geographic footprint are enabling us to respond quickly to changing market dynamics and grow our market share.” Olafsson said that in the generics business, Hikma was “successfully” driving demand for its “more differentiated”; in-market products, and was making progress reducing its cost base. “We achieved good results in the branded business, taking into consideration the usual seasonality. “In the first half, we renewed our focus on advancing our pipnlinee, enhancing our corporate research and development team and accelerating new projects. “More broadly, we are strengthening key functions across the group and bringing new capabilities to ensure we have the right teams in place to take the business forward.” Hikma’s performance in the first half exceeded the board’s expectations, Olafsson said, and it was reportedly “pleased”; to be able to raise its guidance for both the injectables and generics businesses for the full year. “The measures we have taken and investments we have made across the group over the past year are delivering results, but we still have work to do. “Our markets are competitive and we don't expect the same demand for some of our injectable products to continue into 2019,” Siggi Olafsson explained. “This means we must remain focused on strengthening our customer relationships, improving profitability and advancing our pipeline to ensure future growth.”
30/5/2018
09:26
jswjsw: RNS: "London, 30 May 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that its wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp. (West-Ward), has launched Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine(R) .(1) Methylergonovine Maleate Tablets are a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage." ----------------- Why on earth this has caused the share price to tank is just beyond me... j
19/12/2017
20:28
death by donut: Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima(TM) (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima(TM) (rituximab), Remsima(R) (infliximab) and Herzuma(R) (trastuzumab) - in all its MENA markets. Truxima(TM) is mAb biosimilar to Roche's MabThera(R) (rituximab), which is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima(TM) (rituximab) in all of its MENA markets, leveraging Hikma's strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise. Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "We are pleased to be adding Truxima(TM) to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines."
26/6/2017
06:12
broadwood: RNS Number : 0778J Hikma Pharmaceuticals Plc 26 June 2017 Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business London, 26 June 2017 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the fast-growing multinational pharmaceutical group, today announces the planned retirement of Michael Raya, CEO of the US business. Following the significant increase in scale over the last several years, Hikma today also announces organisational changes to the US business (West Ward Pharmaceuticals) as well as a number of senior leadership changes and appointments to reflect its enhanced US market positioning and to better align with the global Hikma organisation. Key changes announced today include: -- Michael Raya, CEO of the US business will retire at the end of this year. Mr Raya has led the US business for more than 25 years and in that time, has demonstrated strong leadership that has enabled Hikma to grow into a top 10 generics company in the US. -- From 1 July 2017, the US business will be organized into two entities both of which will report into the Chairman and CEO, Said Darwazah. There will be a US Generics Division and a US Injectables Division. -- Brian Hoffmann has been promoted to President of the US Generics Division. Mr Hoffmann brings a wealth of experience in strategy, business development, M&A and marketing. Since joining West-Ward/Hikma in 2009, he has been instrumental in the growth of the US business. -- Riad Mishlawi has been promoted to the role of CEO, Injectables Division, responsible for all injectable operations globally, including the newly formed US Injectables Division. Riad brings both breadth and depth to this role, having worked with the company since 1990 and led the Injectables Division through a period of rapid growth. -- Mr Raya will continue to have oversight of the US business, working closely with the team for the rest of the year to transition the business. "I would like to thank Mike for his many years of successful leadership of our US business, and wish him well in his retirement" said Said Darwazah, Chairman and CEO of Hikma. "The leadership and organisational changes we have announced today will bring greater organisational focus and alignment, establish a scalable structure to enable continued growth, and strengthen the US leadership team." Commenting on his retirement, Mr Raya said, "Together with my colleagues, I am proud of what we were able to accomplish during my time at Hikma/West Ward and leave confident that the company is extremely well-positioned for the future
ADVFN Advertorial
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201129 14:37:53